Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Change in Account Payables (2018 - 2025)

Cyclerion Therapeutics has reported Change in Account Payables over the past 7 years, most recently at $18000.0 for Q3 2025.

  • For Q3 2025, Change in Account Payables rose 12.5% year-over-year to $18000.0; the TTM value through Sep 2025 reached $176000.0, up 220.55%, while the annual FY2024 figure was -$445000.0, 74.89% up from the prior year.
  • Change in Account Payables for Q3 2025 was $18000.0 at Cyclerion Therapeutics, up from -$21000.0 in the prior quarter.
  • Over five years, Change in Account Payables peaked at $1.3 million in Q4 2022 and troughed at -$2.1 million in Q2 2023.
  • A 5-year average of -$66894.7 and a median of $16000.0 in 2024 define the central range for Change in Account Payables.
  • Biggest five-year swings in Change in Account Payables: surged 1379.63% in 2022 and later tumbled 931.05% in 2023.
  • Year by year, Change in Account Payables stood at -$311000.0 in 2021, then skyrocketed by 526.05% to $1.3 million in 2022, then plummeted by 70.94% to $385000.0 in 2023, then crashed by 77.66% to $86000.0 in 2024, then crashed by 79.07% to $18000.0 in 2025.
  • Business Quant data shows Change in Account Payables for CYCN at $18000.0 in Q3 2025, -$21000.0 in Q2 2025, and $93000.0 in Q1 2025.